CDH1 and gastric cancer: Due to the high heterogeneity of GC and our limited data based on two selected GC cell lines, the correlation of CDH1 mutations to single agent and doublet treatment of AZD1775, cisplatin, and olaparib deserves to be further studied in expanded GC models, such as patient-derived xenografts, which would better compare the efficacy of combined treatment based on the maximum tolerated dose in vivo and help launch drug efficacy trials in mice prior to their introduction in human trials.